Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
- Why does moderate starvation during sickness can enhance the activity of immune cells?
- WHO experts agree on new name for monkeypox virus variant
- How terrible is the newly discovered “Langya virus” in China?
- ‘Most Expensive Drug’ Zolgensma facing new challenge after Two Children Died
- Hair loss and sexual dysfunction added to list of symptoms of long-COVID along with fatigue and brain fog
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
Another pharmaceutical company gave up its first-generation COVID-19 vaccine research and development! Bayer, CureVac terminate the COVID-19 vaccine
CureVac announced the abandonment of the COVID-19 mRNA vaccine research and development, and the focus of subsequent development shifts to the second-generation vaccine.
On October 12, CureVac announced the withdrawal of its first-generation COVID-19 vaccine candidate CVnCoV from the EMA approval process. This decision also means that the company’s previous 405 million dose vaccine pre-purchase agreement with the European Commission will be terminated.
Prior to August, CureVac and GlaxoSmithKline announced preclinical data on the immune response. The data showed that compared with the first-generation candidate vaccine CVnCoV, the second-generation vaccine candidate CV2CoV better activated the innate and adaptive immune response. , So as to start the immune response faster, and have a higher antibody titer and stronger memory B cell and T cell activation effect.
The company expects to advance the second-generation mRNA vaccine to late-stage clinical practice in the first half of 2022, and seek regulatory approval in the same year.
On September 28, the French pharmaceutical giant Sanofi announced that it would stop the third phase of the messenger ribonucleic acid COVID-19 vaccine. The reason is that the vaccine has missed the best time to market. The company said that it will continue to promote the recombinant protein COVID-19 vaccine. Research and development work.
Bayer AG recently stated that it has terminated a vaccine production partnership under which Bayer will help CureVac produce its COVID-19 vaccine.
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
(source:internet, reference only)
Disclaimer of medicaltrend.org